Last updated: October 31, 2026
Rebinyn is Novo Nordisk’s extended-half-life recombinant factor IX product for hemophilia B. Its commercial position rests on weekly prophylaxis, lower injection frequency than standard half-life factor IX products, and established clinical use. The main threats are gene therapies, competing extended-half-life factor IX products, high treatment costs, and eventual biosimilar competition.
Novo Nordisk does not publicly disclose Rebinyn revenue as a standalone line item. The company reports its hemophilia and rare-blood-disorder products in aggregated categories, so a precise brand-level revenue trajectory cannot be calculated from public filings. The available evidence supports a mature-growth profile: Rebinyn remains commercially relevant, but its long-term market share is exposed to one-time gene therapies and procurement pressure.
What is Rebinyn and how does it compete in hemophilia B?
Rebinyn is nonacog beta pegol, a glycoPEGylated recombinant coagulation factor IX. It is administered intravenously for routine prophylaxis, on-demand treatment and control of bleeding, and perioperative management in adults and children with hemophilia B.
| Attribute |
Rebinyn |
| Active ingredient |
Nonacog beta pegol |
| Drug class |
Extended-half-life recombinant factor IX |
| Developer and marketer |
Novo Nordisk |
| Initial U.S. approval |
2017 |
| Primary indication |
Congenital factor IX deficiency, or hemophilia B |
| Main dosing advantage |
Weekly prophylaxis in many patients |
| Administration |
Intravenous infusion |
| Product type |
Biologic, recombinant coagulation factor |
| Principal competitors |
Alprolix, Idelvion, BeneFIX, Ixinity, Hemgenix and Beqvez |
| U.S. regulatory framework |
Biologics License Application |
| Orange Book status |
Not listed as a conventional small-molecule drug |
The product’s clinical and commercial value comes from its extended half-life. The FDA label identifies routine prophylaxis, on-demand treatment and perioperative management as approved uses. Dosing is individualized based on age, bleeding pattern, body weight, factor recovery and clinical response (FDA, 2017).
What is the commercial market for Rebinyn?
The relevant market is concentrated, specialist-driven and reimbursement-sensitive. Hemophilia B treatment is purchased through a combination of national health systems, specialty pharmacies, hospitals, managed-care plans and hemophilia treatment centers.
Rebinyn competes in four commercial segments:
- Standard half-life recombinant factor IX.
- Extended-half-life factor IX.
- Plasma-derived factor IX.
- Gene therapy intended to reduce or eliminate regular factor replacement.
Extended-half-life products have gained share because they can reduce infusion frequency and improve adherence. Their price per unit is high, but payers may accept the premium when annual factor consumption, bleed rates or treatment burden decline.
How does Rebinyn compare with competing factor IX products?
| Product |
Company |
Technology |
Commercial position |
| Rebinyn |
Novo Nordisk |
PEGylated recombinant factor IX |
Weekly prophylaxis; established global presence |
| Alprolix |
Sanofi/Sobi |
Fc-fusion recombinant factor IX |
Major extended-half-life competitor |
| Idelvion |
CSL Behring |
Albumin-fusion recombinant factor IX |
Long-acting prophylaxis and treatment |
| BeneFIX |
Pfizer |
Standard half-life recombinant factor IX |
Mature product with broad historical use |
| Ixinity |
Medexus |
Recombinant factor IX |
Smaller competitive position |
| Hemgenix |
CSL |
Adeno-associated virus gene therapy |
One-time treatment approach |
| Beqvez |
Pfizer |
Adeno-associated virus gene therapy |
Gene-therapy competitor for selected adults |
Rebinyn’s strongest competitive segment is patients who prefer or require less frequent replacement therapy but are not eligible for, unwilling to receive, or unable to access gene therapy.
What is Rebinyn’s financial trajectory?
Novo Nordisk does not provide separate annual sales for Rebinyn in its public annual reports. The company reports product sales by therapeutic area and groups rare blood-disorder brands within broader reporting categories. This prevents a verified Rebinyn-specific revenue series from being constructed.
What can be inferred from Novo Nordisk’s reporting?
Rebinyn’s financial trajectory is driven by:
- Conversion from standard half-life factor IX products.
- Continued adoption of extended-half-life prophylaxis.
- International reimbursement and tender wins.
- Pediatric and adolescent use.
- Pricing pressure from health-system procurement.
- Competition from Alprolix and Idelvion.
- Gene-therapy uptake in eligible adults.
- Manufacturing capacity and supply continuity.
The brand has a durable revenue base because hemophilia B is a lifelong disorder and many patients remain on factor replacement for years. Revenue growth is likely to be moderate rather than high because the extended-half-life category is established and the broader hemophilia market is increasingly segmented by gene therapy.
A product-level model should not assign Novo Nordisk’s total rare-blood-disorder revenue to Rebinyn. That would overstate the brand because Novo also sells NovoSeven, Esperoct and other products in the category.
When does Rebinyn lose regulatory exclusivity?
Rebinyn received U.S. biologic approval in 2017. Under the Biologics Price Competition and Innovation Act, an originator biologic generally receives 12 years of reference-product exclusivity from first licensure. On that basis, U.S. reference-product exclusivity is expected to run until approximately 2029, subject to the legally operative first-licensure date and any applicable statutory adjustments (42 U.S.C. § 262).
| Exclusivity layer |
Approximate position |
| U.S. reference-product exclusivity |
Approximately 12 years from 2017 approval |
| Expected U.S. biosimilar eligibility window |
Approximately 2029 onward |
| Patent exclusivity |
Depends on individual patent claims, terminal disclaimers and adjustments |
| Pediatric extension |
May extend certain qualifying exclusivity periods if granted |
| European regulatory protection |
Based on EU data and market exclusivity rules, not the U.S. 12-year framework |
Regulatory exclusivity and patent protection are separate. A biosimilar may become eligible after the regulatory exclusivity period while remaining exposed to valid patents. Conversely, a patent expiration does not by itself guarantee immediate biosimilar market entry.
What patents protect Rebinyn?
Rebinyn is protected through a patent estate covering the recombinant factor IX molecule, PEGylation chemistry, conjugation methods, manufacturing processes, formulations and therapeutic use. Publicly available commercial information does not establish a single controlling expiry date for every relevant claim.
The most important patent categories are:
PEGylated factor IX composition patents
These claims may cover the modified factor IX molecule, the location or nature of PEG attachment, and functional characteristics such as coagulation activity or half-life.
Manufacturing and conjugation patents
Process claims may cover recombinant expression, purification, chemical modification, reaction conditions and removal of unreacted PEG or process impurities. These patents can create practical barriers even when composition claims face validity challenges.
Formulation patents
Formulation protection may address protein stability, excipient combinations, pH, storage conditions and lyophilized or reconstituted presentations. These claims can complicate a biosimilar’s route to commercial equivalence.
Method-of-use patents
Potential use claims include prophylaxis, bleeding control and perioperative treatment in hemophilia B. Their value depends on claim scope, enforceability and whether a competing product can launch with a legally compliant label.
Rebinyn is a biologic, so it does not have the standard small-molecule Orange Book patent listing structure. The relevant U.S. regulatory reference is the Purple Book and the biologic patent-dispute framework under Section 351(l) of the Public Health Service Act. The absence of an Orange Book entry does not mean the product lacks patent protection.
What is the Orange Book status of Rebinyn?
Rebinyn is not expected to have a conventional Orange Book listing because it is licensed as a biologic rather than approved as a small-molecule drug under an Abbreviated New Drug Application.
The practical implications are:
- There is no ordinary Orange Book Paragraph IV pathway.
- Biosimilar applicants use the 351(k) pathway.
- Patent disputes follow the biologic patent-exchange process.
- A competitor may challenge patents before or after commercial launch.
- Patent information can be more fragmented than for traditional pharmaceutical products.
Are there Paragraph IV challenges to Rebinyn?
A conventional Paragraph IV challenge is not the applicable mechanism for Rebinyn. Because Rebinyn is a biologic, the relevant challenge would involve a biosimilar application and the patent-disclosure and litigation procedures under Section 351(l).
No widely reported public litigation record establishes a major biosimilar challenge to Rebinyn comparable to high-profile small-molecule Paragraph IV cases. The absence of a reported challenge does not remove future entry risk. Biosimilar developers can pursue confidential patent negotiations, declaratory actions, or litigation tied to a future 351(k) application.
What generic or biosimilar entry risks exist?
The near-term risk is limited by technical complexity and market concentration. The longer-term risk rises as U.S. regulatory exclusivity expires.
Technical barriers
A biosimilar factor IX product must demonstrate a high degree of similarity in structure, activity, pharmacokinetics, immunogenicity and manufacturing consistency. PEGylation adds analytical complexity because the applicant must characterize both the protein and the polymer conjugation profile.
Clinical and commercial barriers
Hemophilia treatment decisions are conservative. Physicians and patients place high value on bleeding control, supply reliability and treatment-center familiarity. A biosimilar must usually offer meaningful savings, contracting support or supply advantages to displace an established extended-half-life product.
Market-entry scenarios
| Scenario |
Market effect |
| No near-term biosimilar |
Rebinyn retains specialist and institutional share |
| Single biosimilar entrant |
Discounting and tender pressure increase |
| Multiple biosimilars |
Net price erosion becomes material |
| Gene therapy expansion |
Chronic factor demand declines in treated patients |
| Limited gene-therapy access |
Rebinyn remains a core prophylaxis option |
How do gene therapies affect Rebinyn demand?
Hemgenix and Beqvez create the most significant structural threat to chronic factor replacement. Both target adults with hemophilia B who meet eligibility criteria, but adoption is constrained by price, durability questions, liver-related considerations, treatment-center capacity, payer approval and patient preference.
Gene therapy does not eliminate the total addressable market. Many patients will remain on factor replacement because of age, preexisting antibodies, medical contraindications, uncertain durability, access limitations or reluctance to receive a one-time gene therapy.
The commercial impact on Rebinyn is therefore likely to be gradual and concentrated in eligible adult patients. Pediatric demand, patients requiring predictable replacement and markets without broad gene-therapy reimbursement remain more defensible.
What is Rebinyn’s geographic market coverage?
Novo Nordisk markets Rebinyn in the United States and multiple international markets, including Europe, subject to country-specific approvals and reimbursement. Commercial uptake varies by:
- National tender systems.
- Hospital and home-infusion infrastructure.
- Reimbursement for extended-half-life products.
- Availability of competing factor IX products.
- Local gene-therapy access.
- Pricing controls and reference-pricing policies.
The United States is commercially important because treatment costs are high and specialty distribution is well developed. Europe and other regulated markets can produce substantial volume but often impose greater price pressure through centralized procurement.
How strong is the Rebinyn patent estate?
Rebinyn’s patent position is strategically meaningful but difficult to evaluate through a single expiry date. The strongest defenses are likely to come from the combination of product, conjugation, formulation and manufacturing claims rather than from one patent alone.
Patent strength is reduced by three factors:
- Biologic competitors can design around individual claims.
- Biosimilar litigation can test claim validity and scope.
- Gene therapy competes without practicing the same factor IX manufacturing claims.
Patent strength is increased by manufacturing complexity, trade-secret know-how, regulatory experience and physician familiarity. These non-patent barriers may remain commercially relevant after individual patents expire.
What licensing deals affect Rebinyn?
Rebinyn was developed and commercialized by Novo Nordisk. No major third-party licensing transaction is publicly identified as the central commercial driver of the product. Its economics are therefore primarily tied to Novo Nordisk’s own development, manufacturing, distribution and contracting strategy.
What is the outlook for Rebinyn revenue?
Rebinyn’s revenue outlook is stable but exposed to gradual erosion. The most likely trajectory is:
- Near term: continued demand from established prophylaxis patients and conversion from standard half-life factor IX.
- Medium term: slower growth as the extended-half-life segment matures and gene therapy expands.
- Around and after U.S. biosimilar eligibility: increased pricing and contracting pressure.
- Long term: a segmented market in which chronic factor replacement remains important but loses selected adult patients to gene therapy.
The principal value driver is not volume expansion alone. It is retention of high-value prophylaxis patients, reimbursement for reduced infusion burden and continued differentiation from standard half-life factor IX products.
Key Takeaways
- Rebinyn is Novo Nordisk’s extended-half-life recombinant factor IX for hemophilia B.
- Its primary advantage is weekly prophylaxis and reduced infusion frequency.
- Novo Nordisk does not disclose Rebinyn revenue separately, preventing a verified brand-level financial series.
- Rebinyn competes directly with Alprolix and Idelvion and indirectly with Hemgenix and Beqvez.
- The product is not an Orange Book drug and is not subject to a conventional Paragraph IV challenge.
- U.S. biologic exclusivity is expected to extend approximately 12 years from its 2017 approval, with biosimilar eligibility emerging around 2029.
- Patent risk depends on composition, PEGylation, formulation, manufacturing and method-of-use claims.
- The largest commercial threats are gene-therapy adoption, biosimilar entry and payer-driven price compression.
- Manufacturing complexity and physician familiarity provide protection beyond formal patent expiry.
FAQs
Is Rebinyn a gene therapy?
No. Rebinyn is a recombinant factor IX replacement biologic. Hemgenix and Beqvez are gene therapies intended to produce endogenous factor IX expression.
Is Rebinyn better than Alprolix?
Neither product is universally superior. Both are extended-half-life factor IX therapies. Selection depends on dosing interval, pharmacokinetics, bleeding history, patient preference, reimbursement and physician assessment.
Can a biosimilar replace Rebinyn?
A biosimilar could compete after applicable regulatory exclusivity and patent barriers expire. Substitution will depend on FDA approval, interchangeability status, payer contracts and physician adoption.
Does Rebinyn require refrigeration?
Rebinyn storage requirements depend on the presentation and jurisdiction. The U.S. prescribing information specifies product-specific storage and reconstitution conditions that should govern distribution and use (FDA, 2017).
What is the biggest long-term risk to Rebinyn sales?
The largest structural risk is the migration of eligible adults from chronic factor replacement to gene therapy. Biosimilar competition is a later risk but may create more direct price erosion once regulatory and patent barriers decline.
References
-
Food and Drug Administration. (2017). Rebinyn prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
Novo Nordisk A/S. (2024). Annual report 2023. Bagsværd, Denmark: Novo Nordisk A/S.
-
Novo Nordisk A/S. (2025). Annual report 2024. Bagsværd, Denmark: Novo Nordisk A/S.
-
European Medicines Agency. (2017). Rebinyn: EPAR - product information. European Union.
-
Public Health Service Act, 42 U.S.C. § 262.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, § 7002.